Treatment of Influenza with Severe Pneumonia and Respiratory Failure in Hospitalized Patients
Clinical Scenario
This protocol covers the management of influenza in patients who require hospitalization with severe lower respiratory tract involvement. It applies to persons of any age, regardless of illness duration prior to admission.
The scenario encompasses the following presentations:
Severe lower respiratory tract disease
Pneumonia
Respiratory failure
Acute respiratory distress syndrome (ARDS)
Why Severity Matters Here
Influenza-associated pneumonia and respiratory failure represent a distinct, high-acuity clinical situation. The degree of lower respiratory tract compromise — from pneumonia through ARDS — shapes both the urgency of intervention and the scope of assessment required. Critically ill patients face additional risks that the protocol specifically addresses.
Treatment Approach (Overview Only)
Antiviral therapy started as early as possible is central to management. The protocol specifies preferred and alternative antiviral options based on the patient's ability to receive enteric medications — a clinically relevant distinction at this severity level.
For patients presenting with extensive pneumonia, respiratory failure, or hypotension, the protocol additionally directs evaluation and empiric treatment of bacterial coinfection, with specific coverage considerations for critically ill patients.
Drug selection, dosing, duration, and the full sequencing algorithm are detailed in the complete structured protocol below.
References
DOI: 10.1093/cid/ciy866
Persons of any age who are hospitalized with influenza, regardless of illness duration prior to hospitalization (A-II).
In hospitalized adults, oseltamivir is the preferred antiviral drug because data are very limited on inhaled zanamivir in severely ill influenza patients.
Clinicians should investigate and empirically treat bacterial coinfection in patients with suspected or laboratory-confirmed influenza who present initially with severe disease (extensive pneumonia, respiratory failure, hypotension, and fever), in addition to antiviral treatment for influenza (A-II).
Given the higher incidence of S. aureus infections, including MRSA among patients with severe pneumonia complicating influenza, agents with activity against MRSA should be included in the empiric treatment regimen for critically ill patients.
View source ↗